Navigation Links
PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/10/2008

ANNAPOLIS, Md., March 10 /PRNewswire-FirstCall/ -- PharmAthene, Inc., (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that David P. Wright, President and Chief Executive Officer of PharmAthene, will present at the Cowen and Company 28th Annual Health Care Conference in Boston on Tuesday, March 18, 2008 at 8:45 a.m. The presentation is scheduled to take place in the Vineyard Room at the Boston Marriott Copley Place hotel.

PharmAthene's presentation will be available via webcast on the company's website at http://www.pharmathene.com. A link to access the webcast will be accessible from both the homepage and the investor relations pages of the PharmAthene corporate website. For assistance, contact Stacey Jurchison at 410-269-2610.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytic..." or the "Company") today announced updated result... in patients with sarcomas metastatic to the lung ...tive Tissue Oncology Society Meeting held in Miami...ter presentation, entitled "A Phase II Study of In...
(Date:11/6/2009)... The agenda for Arrowhead&rsquo...nce, which is set to take place on February 22-24,... three day conference we will highlight key issues...ers to share their experiences. , ...-- The agenda for Arrowhead’s 2010 Personal...
(Date:11/5/2009)...GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -...s financial results for the third quarter ended Se....6 million ($0.04 per share) for the three months ... $6.8 million ($0.08 per share) in the comparable ...er 30, 2009, GenVec,s net loss was $14.1 million (...
(Date:11/5/2009)...PARSIPPANY, N.J., Nov. 5 DSM Pharm...e a manufacturing alliance with Galenix, Saint Jea... commercial scale manufacturing partner for Galeni... and Galenix will collaborate on business developm...ry technologies, based on the strength of Galenix ...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...sident of Finance -, HOPKINTON, Mass., April 3, 2...today announced the promotion of Peter F.,McAree t...r. McAree,previously served as Vice President of F...ns will step down from the position of CFO., McAr...and public,accounting experience. Previously, McAr...
...e Israeli,scientists, in a recent survey on creati...ds that could "put them into a creative state and ...ponsored by the,Jerusalem-based Project Mind Found...urprisingly revealed that, even when the issue of ...essed a medium or high level of,willingness to try...
...ics, Inc. (Nasdaq: PCYC ) today announced multipl...ne disease drug candidates at the,American Associa...g being,held April 12-16, 2008, at the San Diego C...tations relate to the company,s histone deacetylas...hase 1 clinical trial, and the,use of proprietary ...
Other Biology Technology:Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 2Project Mind Survey of Israeli Ph.D. Scientists Favors a New Standard of Creativity in Science 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 2Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 3Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting 4
(Date:11/4/2009)... CARLSBAD, Calif., Nov. 4 GenVault...illiam Brody, M.D., Ph.D., has joined its Board of...ial Chair of the Salk Institute, is an acclaimed p...o joining the Salk Institute, Dr. Brody served as ...a member of the National Academy of Engineering an...
(Date:11/3/2009)...DISON, WI, NOVEMBER 4, 2009 -- The world,s greate...ng grape variety, human input, and something calle...eyard site, soil, and climate. , Experts will ...n a symposium on Wednesday, Nov. 4 in Pittsburgh. ... presented in two parts at the 2009 Annual Meeting...
(Date:11/3/2009)... white shark may be the ultimate loner of the ocea... but a team of researchers has discovered that the...of migration that over tens of thousands of years ... have separated themselves into a population genet.... , "White sharks are a large, highly mobile spe...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Great wines come from great soils 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market According to Millennium Research Group 49010 1Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market According to Millennium Research Group 49010 2Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference 12643 1Scottsdale Facility to Be First in U S to Showcase True REST Technology 4597 1Scottsdale Facility to Be First in U S to Showcase True REST Technology 4597 2Scottsdale Facility to Be First in U S to Showcase True REST Technology 4597 3
...of the first trial of the effect of male circumcis...andmark trial," will be published in PLoS Medicin...n reduced the rate of new infections among heteros...e HIV infection rates are generally lower among Af...ractice, compared with largely non-circumcised pop...
... Linda Gill Heart Institute at the University of K...clotting therapy. The drug and its antidote are be...g blood clots while at the same time providing phy... of the blood thinner to help safeguard patients a...on patients are prescribed so-called "blood thinne...
...r Medicine uses PET, radiotracer to track enzyme i... to reduce a key enzyme in the lungs, possibly con...effects, according to a study published in the Sep...he study, which used a radiotracer to track the en...ation of the tracer in the bloodstream than nonsmo...
Other Biology News:PLoS Medicine publishes first trial of effect of male circumcision on HIV infection 2PLoS Medicine publishes first trial of effect of male circumcision on HIV infection 3UK is first to administer new anti-clotting technology 2Smoking damages key regulatory enzyme in the lung 2Smoking damages key regulatory enzyme in the lung 3
Armenian Hamster Anti-Mouse CD48 Monoclonal Antibody, Biotin Conjugated, Clone HM48-1 from BioLegend
Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.
Mouse Anti-Pim-1 Monoclonal Antibody, Unconjugated, Clone 12H8 from Santa Cruz Biotechnology, Inc.
Canine IL-4 ELISpot Kit from R&D Systems
Biology Products: